We recognized that targeting CCR2+ monocyte–mediated Mo-AM depletion could also result in the defective generation of other CCR2+ monocyte–derived cells that may contribute to BOS, such as iMacs and CD11b+ DCs (26). The gene discussed is CCR2; the disease is Buschke-Ollendorff syndrome.